| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1375782 | Bioorganic & Medicinal Chemistry Letters | 2008 | 5 Pages |
Abstract
A novel bifunctional maleimido CHX-A″ DTPA chelator 5 was developed and conjugated to the monoclonal antibody trastuzumab (Herceptin) and subsequently radiolabeled with 111In. The resulting 111In labeled immunoconjugate 2 was demonstrated to bind to SKOV-3 ovarian cancer cells comparably to an isothiocyanato CHX-A″ DTPA modified native trastuzumab, 1. Through efficient thiol-maleimide chemistry, antibodies, peptides or other targeting vectors can now be modified with an established radioactive metal chelating agent CHX-A″ DTPA for imaging and/or therapies of cancer.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Heng Xu, Kwamena E. Baidoo, Karen J. Wong, Martin W. Brechbiel,